New hope for nerve disease patients who fail standard treatments
NCT ID NCT07154524
First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 43 times
Summary
This study looks at whether a blood-filtering procedure called immunoadsorption can help people with chronic inflammatory demyelinating polyneuropathy (CIDP) who do not get better with standard treatments like intravenous immunoglobulins or steroids. About 140 adults with CIDP will be observed for 18 months. If their current treatment stops working, they may switch to immunoadsorption, and researchers will track their symptoms and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Ulm
RECRUITINGUlm, Baden-Wurttemberg, 89081, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.